220 related articles for article (PubMed ID: 30580002)
21. Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer.
Tulsyan S; Das CJ; Tripathi M; Seth A; Kumar R; Bal C
Nucl Med Commun; 2017 Dec; 38(12):1094-1102. PubMed ID: 28957842
[TBL] [Abstract][Full Text] [Related]
22. Comparison of
Zhang Q; Zang S; Zhang C; Fu Y; Lv X; Zhang Q; Deng Y; Zhang C; Luo R; Zhao X; Wang W; Wang F; Guo H
J Transl Med; 2017 Nov; 15(1):230. PubMed ID: 29115970
[TBL] [Abstract][Full Text] [Related]
23. Retrospective correlation of
Onal C; Torun N; Oymak E; Guler OC; Reyhan M; Yapar AF
Ann Nucl Med; 2020 Jun; 34(6):388-396. PubMed ID: 32221791
[TBL] [Abstract][Full Text] [Related]
24. Comparison of
Schwenck J; Rempp H; Reischl G; Kruck S; Stenzl A; Nikolaou K; Pfannenberg C; la Fougère C
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):92-101. PubMed ID: 27557844
[TBL] [Abstract][Full Text] [Related]
25. Frusemide aids diagnostic interpretation of
Fennessy N; Lee J; Shin J; Ho B; Ali SA; Paschkewitz R; Emmett L
J Med Imaging Radiat Oncol; 2017 Dec; 61(6):739-744. PubMed ID: 28623852
[TBL] [Abstract][Full Text] [Related]
26.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
27.
Vinsensia M; Chyoke PL; Hadaschik B; Holland-Letz T; Moltz J; Kopka K; Rauscher I; Mier W; Schwaiger M; Haberkorn U; Mauer T; Kratochwil C; Eiber M; Giesel FL
J Nucl Med; 2017 Dec; 58(12):1949-1955. PubMed ID: 28637799
[No Abstract] [Full Text] [Related]
28. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.
Rauscher I; Maurer T; Beer AJ; Graner FP; Haller B; Weirich G; Doherty A; Gschwend JE; Schwaiger M; Eiber M
J Nucl Med; 2016 Nov; 57(11):1713-1719. PubMed ID: 27261524
[TBL] [Abstract][Full Text] [Related]
29. Detection Rate and Localization of Prostate Cancer Recurrence Using
Kranzbühler B; Müller J; Becker AS; Garcia Schüler HI; Muehlematter U; Fankhauser CD; Kedzia S; Guckenberger M; Kaufmann PA; Eberli D; Burger IA
J Nucl Med; 2020 Feb; 61(2):194-201. PubMed ID: 31375566
[TBL] [Abstract][Full Text] [Related]
30. Clinical performance of
Kranzbühler B; Nagel H; Becker AS; Müller J; Huellner M; Stolzmann P; Muehlematter U; Guckenberger M; Kaufmann PA; Eberli D; Burger IA
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):20-30. PubMed ID: 29032394
[TBL] [Abstract][Full Text] [Related]
31. PSMA PET/CT with Glu-urea-Lys-(Ahx)-[⁶⁸Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer.
Giesel FL; Fiedler H; Stefanova M; Sterzing F; Rius M; Kopka K; Moltz JH; Afshar-Oromieh A; Choyke PL; Haberkorn U; Kratochwil C
Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1794-800. PubMed ID: 26162799
[TBL] [Abstract][Full Text] [Related]
32. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.
van Leeuwen PJ; Stricker P; Hruby G; Kneebone A; Ting F; Thompson B; Nguyen Q; Ho B; Emmett L
BJU Int; 2016 May; 117(5):732-9. PubMed ID: 26683282
[TBL] [Abstract][Full Text] [Related]
33.
Ahmadzadehfar H; Azgomi K; Hauser S; Wei X; Yordanova A; Gaertner FC; Kürpig S; Strunk H; Essler M
J Nucl Med; 2017 Mar; 58(3):438-444. PubMed ID: 27660148
[TBL] [Abstract][Full Text] [Related]
34. Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer.
Park SY; Zacharias C; Harrison C; Fan RE; Kunder C; Hatami N; Giesel F; Ghanouni P; Daniel B; Loening AM; Sonn GA; Iagaru A
Radiology; 2018 Aug; 288(2):495-505. PubMed ID: 29786490
[TBL] [Abstract][Full Text] [Related]
35. MRI versus ⁶⁸Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer.
Zamboglou C; Wieser G; Hennies S; Rempel I; Kirste S; Soschynski M; Rischke HC; Fechter T; Jilg CA; Langer M; Meyer PT; Bock M; Grosu AL
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):889-897. PubMed ID: 26592938
[TBL] [Abstract][Full Text] [Related]
36. Whole-Body Integrated [
Guberina N; Hetkamp P; Ruebben H; Fendler W; Grueneisen J; Suntharalingam S; Kirchner J; Puellen L; Harke N; Radtke JP; Umutlu L; Hadaschik BA; Herrmann K; Forsting M; Wetter A
Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
[TBL] [Abstract][Full Text] [Related]
37.
Kopp J; Kopp D; Bernhardt E; Manka L; Beck A; Gerullis H; Karakiewicz P; Schoerner W; Hammerer P; Schiffmann J
World J Urol; 2020 Dec; 38(12):3085-3090. PubMed ID: 32103332
[TBL] [Abstract][Full Text] [Related]
38.
Ceci F; Castellucci P; Graziani T; Farolfi A; Fonti C; Lodi F; Fanti S
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):31-39. PubMed ID: 30350010
[TBL] [Abstract][Full Text] [Related]
39.
Cytawa W; Seitz AK; Kircher S; Fukushima K; Tran-Gia J; Schirbel A; Bandurski T; Lass P; Krebs M; Połom W; Matuszewski M; Wester HJ; Buck AK; Kübler H; Lapa C
Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):168-177. PubMed ID: 31529265
[TBL] [Abstract][Full Text] [Related]
40. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]